SHELA BAZILE: Open Payments
NPI 1780022590 · DEERFIELD BEACH, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,040 in 35 payments from 21 companies in 2025. Trend: 2023 $451 · 2024 $637 · 2025 $1,040
Food & beverage: $1,040
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 3 | $173 |
| Genmab U.S., Inc. | 3 | $98 |
| TerSera Therapeutics LLC | 3 | $88 |
| E.R. Squibb & Sons, L.L.C. | 2 | $65 |
| Janssen Biotech, Inc. | 2 | $58 |
| Sumitomo Pharma America, Inc. | 2 | $56 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $54 |
| Incyte Corporation | 2 | $52 |
| Celgene Corporation | 1 | $46 |
| ABBVIE INC. | 2 | $45 |
Products named: OJJAARA, Epkinly, OPDIVO, ORGOVYX, REBLOZYL, VENCLEXTA, Stimufend, Quzyttir.
Industry payments across FL — which companies pay providers there.
